Denali Therapeutics got an extension from the Food and Drug Administration for the review of its treatment for the genetic disorder Hunter syndrome. The target date for the license application review ...
The FDA granted fast track status to ADCE-D01, a targeted drug in early trials for soft tissue sarcoma, to speed development ...
A team of researchers at the University of Kentucky Sanders-Brown Center on Aging now have a better understanding of how the ...
Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated ...
The International Union for Conservation of Nature (IUCN) issued a decision on October 9, 2025, to retain the "Endangered" ...
Sources from a University of Mississippi Press Release say that Liver cancer is the third-leading cause of cancer deaths ...
Policy brief urges balanced animal-research rules, offering science blogs NABR IUCN keywords and full statement.
Integrative approaches to addressing both mental and physical health may be the next step in successful treatment for ...
Seattle biotech companies are using AI to design new medical treatments, but scientists caution the tech holds enormous ...
Multiple sclerosis (MS) is a chronic autoimmune disease affecting more than 2.9 million people worldwide. It occurs when the ...
Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback